Most clinical trials involve the assessment of treatment effects in multiple subgroups, either on a planned or unplanned basis. It is well-known that the resulting statistical tests are susceptible to misinterpretation if used uncritically. Methods for addressing these interpretational problems, including tests of interaction and Bonferonni procedures, are discussed and illustrated. The need to specify subgroup analyses in advance is emphasized.
FleissJL. The Design and Analysis of Clinical Experiments. New York: John Wiley and Sons; 1986.
2.
HjalmarsonAElmfeldtDHerlitzJHolmbergSMalekINybergGRydenLSwedbergKVedinAEffect on mortality of metoprolol in acute myocardial infarction. The Lancet. 1981;October: 823–827.
3.
PocockSJ. Clinical Trials: A Practical Approach. Chichester, England: John Wiley & Sons; 1983.
4.
StallonesRA. The use and abuse of subgroup analysis in epidemiological research. Preventive Med.1987;16: 183–194.
5.
RothmanKJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1: 43–46.
6.
PetoRPikeMCArmitagePDesign and analysis of randomized clinical trials requiring prolonged observation on each patient: I. Introduction and design. Br J Cancer. 1976;84: 585–612.
7.
BulpittCJ. Subgroup analysis. The Lancet. 1988;July:31–34.
8.
PocockSJHughesMDLeeRJ. Statistical problems in the reporting of clinical trials: a survey of three medical journals. New England J Med.1987;317(7):426–432.
9.
LeeKLMcNeerJFStarmerCEClinical judgement and statistics: lessons from a simulated randomized trial in coronary artery disease. Circulation. 1980;61: 508–515.
10.
SimonR. Patient subsets and variations in therapeutic efficacy. Br J Clin Pharmacology. 1982;14: 473–482.
11.
SimonR. Statistical tools for subset analysis in clinical trials. In: BaumMKayRScheurleinH (eds). Recent Results in Cancer Research. Heidelberg: Springer-Verlag; 1988.
12.
RocketteHECaplanRJ. Heterogeneous treatment effects: strategies for subgroup analysis in clinical trials. In: BaumMKayRScheurleinH (eds.) Recent Results in Cancer Research. Heidelberg: Springer-Verlag; 1988.
ShusterJvan EysJ. Interaction between prognostic factors and treatment. Controlled Clin Trials. 1983;4: 209–214.
15.
GailMSimonR. Testing for quantitative interactions between treatment effects and patient subsets. Biometrics, 1985;41:361–372.
16.
PetoR. Statistical aspects of cancer trials. In: HainanKE (ed), Treatment of Cancer. London; Chapman and Hall: 1982.
17.
ByarDPGreenSB. The choice of treatment for cancer patients based on covariate information: Application to prostate cancer. Bulletin du Cancer (Paris). 1980;67: 477–490.
18.
ŠidákZ. On probabilities of rectangles in multivariate Student distributions: their dependence on correlations. Ann Math Stat. 1968;42: 169–175.
19.
HolmS. A simple sequentially rejective multiple test procedure. Scandinavian J Stat. 1979;6: 65–70.
20.
ShafferJP. Modified sequentially rejective multiple test procedures. J Am Stat Assoc. 1986;81(395):826–831.
21.
HochbergY. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75(4):800–802.
22.
HochbergYBenjaminiY. More powerful procedures for multiple significance testing. Stat Med.1990;9: 811–818.
23.
SimesRJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika. 1986;73(3):751–754.
24.
McCormickJBKingIJWebbPALassa fever: effective therapy with ribavirin. New England J Med.1986;314(1):20–26.
25.
SimonR. A decade of progress in statistical methodology for clinical trials. Stat Med.1991;10: 1789–1818.
26.
LouisTA. Estimating a population of parameter values using Bayes and empirical Bayes methods. J Am Stat Assoc. 1984;79: 393–398.
27.
BerryDA. Monitoring accumulating data in a clinical trial. Biometrics. 1989;45: 1197–1211.
28.
DurrlemanSSimonR. The effect of diltiazem on mortality and reinfarction after myocardial infarction. New England J Med.1989;320: 123.
29.
DavisCELeffingwellDP. Empirical Bayesian estimates of subgroup effects in clinical trials. Controlled Clinical Trials. 1990;11: 37–42.
30.
DonnerA. A Bayesian approach to the interpretation of subgroup differences in clinical trials. J Chronic Diseases. 1982;35: 429–435.
31.
DixonDOSimonR. Bayesian subset analysis in a colorectal cancer clinical trial. Stat Med.1992;11: 13–22.
32.
MeinertCL. Clinical Trials: Design, Conduct, and Analysis. New York: Oxford University Press; 1986.
33.
ThomasPCSiemiatyckiJDewarRRobinsJGoldbergMArmstrongBG. The problem of multiple inferences in studies designed to generate hypotheses. Am J Epidemiology. 1985;122: 1080–1095.
34.
YusufSWittesJProbstfieldJTyrolerHA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266(1):93–98.
35.
Coronary Drug Project Research Group.Influence of Adherence to Treatment and Response of Cholesterol on Mortality in the Coronary Drug Project. New England J Med.1980;303:1038–1041.
CollinsRGrayRGodwinJPetoR. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: The need for systematic overviews. Stat Med.1987;6: 245–250.
